Evaluation of a 2-Pyridone, KRQ-10018, against Mycobacterium tuberculosis In Vitro and In Vivo

A novel subclass of quinolones, 2-pyridones, showed potent activity against Mycobacterium tuberculosis, with KRQ-10018 being an early lead. KRQ-10018 showed better activity in vitro against M. tuberculosis versus moxifloxacin. In vivo efficacy of KRQ-10018 at 300 mg/kg of body weight was similar to...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lenaerts, Anne J., Bitting, Casey, Woolhiser, Lisa, Gruppo, Veronica, Marietta, Karen S., Johnson, Christine M., Orme, Ian M.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology (ASM) 2008
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2292560/
https://ncbi.nlm.nih.gov/pubmed/18268091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00897-07
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires